US regulator to expedite review of gut microbiome protector product from COMBACTE partner
The US FDA grants ‘fast track designation’ to Da Volterra’s DAV132 for the prevention of Clostridioides difficile infection
Site Search
Site Search
Displaying results 1 - 10 of 773
Neuropathic pain was classified in a way that stymied research. Not anymore
EUROPAIN’s evidence that neuropathic pain patients should be grouped by their pain perception and not the event that sparked it has convinced the European regulator to change its guidelines
Machine learning models outperform traditional selection methods for recruiting osteoarthritis trial patients
APPROACH showed that the models were better at predicting whose disease would progress, thereby making drug testing more effective
Researchers tackle the product-agnostic problems that plague pain drug research
When it comes to what matters most to patients, the alleviation of pain is often top of the list. But designing clinical trials for new analgesics has proven particularly troublesome
Innovative Health Initiative
On 23 February 2021, the European Commission published a proposal for a Single Basic Act establishing a number of joint undertakings under Horizon Europe, including the Innovative Health Initiative (IHI). The European Commission’s proposal is now being discussed by the Council ...
Focus on: vaccines
In March we focussed on IMI vaccine research projects.
Question and answers session on the financial reporting of IMI2 in-kind contributions
On 25 March 2021, IMI and EFPIA held a Q&A session to help EFPIA companies and Associated Partners preparing their IMI2 in-kind contribution financial reports, which have to be submitted by 30 April 2021 via the Sofia tool. The session was not recorded, but answers to all the ...
A quick, cheap and non-invasive way to measure osteoarthritis
APPROACH found that a commercially-available motion-measuring technology could be used to gauge the extent of OA as an alternative or add-on to existing diagnostic options
A recipe for the next disaster: a new, pan-virus methodology for ramping up vaccine production
ZAPI have put in place a new pan-virus methodology for ramping up the production of new vaccines in the next crisis
